Related references
Note: Only part of the references are listed.The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis
Jingyuan Xie et al.
NATURE COMMUNICATIONS (2020)
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy
F. C. Fervenza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A First Step toward a New Approach to Treating Membranous Nephropathy
Piero Ruggenenti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
MENTOR heralds a new era of therapy for membranous nephropathy
Aikaterini Nikolopoulou et al.
NATURE REVIEWS NEPHROLOGY (2019)
Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort
Xin Wang et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
The Genetic and Environmental Factors of Primary Membranous Nephropathy: An Overview from China
Xiao-dan Zhang et al.
KIDNEY DISEASES (2018)
Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up
Karine Dahan et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy
Jan A. J. G. van den Brand et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Treatment of membranous nephropathy: time for a paradigm shift
Piero Ruggenenti et al.
NATURE REVIEWS NEPHROLOGY (2017)
Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series
Frank B. Cortazar et al.
BMC NEPHROLOGY (2017)
Rituximab for the treatment of membranous nephropathy: a single-center experience
Andreja Ales Rigler et al.
CLINICAL NEPHROLOGY (2017)
Primary Membranous Nephropathy
William G. Couser
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Membranous Nephropathy: Pilot Study of a Novel Regimen Combining Cyclosporine and Rituximab
Meryl Waldman et al.
KIDNEY INTERNATIONAL REPORTS (2016)
Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy
Piero Ruggenenti et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Phospholipase A2 Receptor Autoantibodies and Clinical Outcome in Patients with Primary Membranous Nephropathy
Elion Hoxha et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Rituximab in Idiopathic Membranous Nephropathy
Piero Ruggenenti et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Efficacy and Safety of Rituximab Second-Line Therapy for Membranous Nephropathy: A Prospective, Matched-Cohort Study
Paolo Cravedi et al.
AMERICAN JOURNAL OF NEPHROLOGY (2011)
Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous Nephropathy
Laurence H. Beck et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study
Fernando C. Fervenza et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Human Idiopathic Membranous Nephropathy -- A Mystery Solved?.
Richard J. Glassock
NEW ENGLAND JOURNAL OF MEDICINE (2009)
M-Type Phospholipase A(sub 2) Receptor as Target Antigen in Idiopathic Membranous Nephropathy.
Laurence H. Beck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Rituximab treatment of idiopathic membranous nephropathy
F. C. Fervenza et al.
KIDNEY INTERNATIONAL (2008)
The impact of sex in primary glomerulonephritis
Daniel C. Cattran et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy
Paolo Cravedi et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Rituximab for idiopathic membranous nephropathy: Who can benefit?
Piero Ruggenenti et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Management of membranous nephropathy: When and what for treatment
D Cattran
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Rituximab for idiopathic membranous nephropathy
G Remuzzi et al.
LANCET (2002)
Share Paper
